The word “Vyluma,” originates from different languages across the globe and carries the meaning to expand and open to light. This reflects our goal to serve a global population by providing meaningful and effective pharmaceutical ophthalmic solutions.

Today, nearly 4 billion people live with a disorder that prevents the eye from properly processing light the way a normal, healthy eye would. Without improving the quality of treatments available to prevent vision loss and deterioration, projections expect more than 5 billion people could experience some form of vision loss by 2050.  Our leading pipeline program, NVK002, addresses this great unmet need to slow down the progression of myopia in children so they are not at risk for blinding diseases in their future.

Our work aims to curb this projection and improve the treatment quality of disorders affecting so many. In collaboration with pharmaceutical partners, we are working to develop treatments for myopia, presbyopia, night vision disturbance, acute ocular pain, hyperopia, and other eye disorders.